Since mutated IDH is found exclusively in IDH-mutant tumor cells and plays a central role in gliomagenesis, this mutated enzyme was hypothesized to be an ideal therapeutic target and led to the development of treatments blocking mutant IDH (Figure 1). Here, IDH2 is linked to neoplasm.